EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects

Xi Chen, Devjit Tripathy iD, Robert Chilton, Andrea Hansis-Diarte, Marzieh Salehi, Carolina Solis-Herrera iD, Eugenio Cersosimo iD, Ralph A DeFronzo iD

Diabetes · 2024

DOI: 10.2337/db23-0457 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, 2024. Verfasst von Xi Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Kidney, Liver. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, Astra Zeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute and chronic sodium–glucose cotransporter 2 (SGLT-2) inhibition increases endogenous glucose production (EGP). However, the organ—liver versus kidney—responsible for the increase in EGP has not been identified. In this study, 20 subjects with type 2 diabetes (T2D) and 12 subjects with normal glucose tolerance (NGT) received [3-3H]glucose infusion (to measure total EGP) combined with arterial and renal vein catheterization and para-aminohippuric acid infusion for determination of renal blood flow. Total EGP, net renal arteriovenous balance, and renal glucose production were measured before and 4 h after dapagliflozin (DAPA) and placebo administration. Following DAPA, EGP increased in both T2D and NGT from baseline to 240 min, while there was a significant time-related decrease after placebo in T2D. Renal glucose production at baseline was <5% of basal EGP in both groups and did not change significantly following DAPA in NGT or T2D. Renal glucose uptake (sum of tissue glucose uptake plus glucosuria) increased in both T2D and NGT following DAPA (P < 0.05 vs. placebo). The increase in renal glucose uptake was entirely explained by the increase in glucosuria. A single dose of DAPA significantly increased EGP, which primarily is explained by an increase in hepatic glucose production, establishing the existence of a novel renal-hepatic axis. Article Highlights

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesBenzhydryl CompoundsKidneyLiverDiabetes Mellitus, Type 2GlucoseHumansMaleFemaleMiddle AgedAdultSodium-Glucose Transporter 2 InhibitorsBlood Glucose

Substanzen

GlucosidesBenzhydryl CompoundsGlucoseSodium-Glucose Transporter 2 InhibitorsBlood Glucosedapagliflozin

Autor:innen und Institutionen

  • Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX.
  • Audie L. Murphy Memorial Veterans' Hospital, South Texas Veterans Affairs Heath Care System, San Antonio, TX.

ORCID-Profile: Devjit Tripathy, Carolina Solis-Herrera, Eugenio Cersosimo, Ralph A DeFronzo

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • Astra Zeneca
  • National Institutes of Health

Zitieren

APA

Chen, X., Tripathy, D., Chilton, R., Hansis-Diarte, A., Salehi, M., Solis-Herrera, C., Cersosimo, E., & DeFronzo, R. A. (2024). Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects. Diabetes. https://doi.org/10.2337/db23-0457

Vancouver

Chen X, Tripathy D, Chilton R, Hansis-Diarte A, Salehi M, Solis-Herrera C, et al. Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects. Diabetes. 2024. doi:10.2337/db23-0457

BibTeX
@article{Chen2024,
  author = {Chen, Xi and Tripathy, Devjit and Chilton, Robert and Hansis-Diarte, Andrea and Salehi, Marzieh and Solis-Herrera, Carolina and Cersosimo, Eugenio and DeFronzo, Ralph A},
  title = {Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects},
  journal = {Diabetes},
  year = {2024},
  doi = {10.2337/db23-0457}
}
Kostenlos starten →